Literature DB >> 23435097

Evaluation of the metal binding sites in a recombinant coagulation factor VIII identifies two sites with unique metal binding properties.

Lars Anders Svensson1, Lars Thim, Ole Hvilsted Olsen, Else Marie Nicolaisen.   

Abstract

Coagulation factor VIII is a glycosylated, non-covalent heterodimer consisting of a heavy chain (A1-A2-B domains) and a light chain (A3-C1-C2 domains). The association of the chains, and the stability and function of the dimer depend on the presence of metal ions. We applied X-ray fluorescence, X-ray crystallographic structure determination with anomalous signals at different wavelengths, and colorimetric measurements to evaluate the metal binding sites in a recombinant factor VIII molecule, turoctocog alfa. We identified a metal binding site in domain A3 dominated by Cu(+) binding and a site in domain A1 dominated by Zn(2+) binding.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23435097     DOI: 10.1515/hsz-2012-0298

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  13 in total

1.  Factor VIII Interacts with the Endocytic Receptor Low-density Lipoprotein Receptor-related Protein 1 via an Extended Surface Comprising "Hot-Spot" Lysine Residues.

Authors:  Maartje van den Biggelaar; Jesper J Madsen; Johan H Faber; Marleen G Zuurveld; Carmen van der Zwaan; Ole H Olsen; Henning R Stennicke; Koen Mertens; Alexander B Meijer
Journal:  J Biol Chem       Date:  2015-04-21       Impact factor: 5.157

2.  Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A.

Authors:  Joerg Kahle; Aleksander Orlowski; Diana Stichel; John F Healey; Ernest T Parker; Marc Jacquemin; Manuela Krause; Andreas Tiede; Dirk Schwabe; Pete Lollar; Christoph Königs
Journal:  Blood       Date:  2017-05-15       Impact factor: 22.113

3.  Evidence That Factor VIII Forms a Bivalent Complex with the Low Density Lipoprotein (LDL) Receptor-related Protein 1 (LRP1): IDENTIFICATION OF CLUSTER IV ON LRP1 AS THE MAJOR BINDING SITE.

Authors:  Patricia A Young; Mary Migliorini; Dudley K Strickland
Journal:  J Biol Chem       Date:  2016-10-29       Impact factor: 5.157

4.  Membrane Interaction of the Factor VIIIa Discoidin Domains in Atomistic Detail.

Authors:  Jesper J Madsen; Y Zenmei Ohkubo; Günther H Peters; Johan H Faber; Emad Tajkhorshid; Ole H Olsen
Journal:  Biochemistry       Date:  2015-09-30       Impact factor: 3.162

5.  The 3.2 Å structure of a bioengineered variant of blood coagulation factor VIII indicates two conformations of the C2 domain.

Authors:  Ian W Smith; Anne E d'Aquino; Christopher W Coyle; Andrew Fedanov; Ernest T Parker; Gabriela Denning; Harold Trent Spencer; Pete Lollar; Christopher B Doering; Paul Clint Spiegel
Journal:  J Thromb Haemost       Date:  2019-09-08       Impact factor: 5.824

6.  Lipid nanotechnologies for structural studies of membrane-associated proteins.

Authors:  Svetla Stoilova-McPhie; Kirill Grushin; Daniela Dalm; Jaimy Miller
Journal:  Proteins       Date:  2014-07-03

7.  Dimeric Organization of Blood Coagulation Factor VIII bound to Lipid Nanotubes.

Authors:  Daniela Dalm; Jesus G Galaz-Montoya; Jaimy L Miller; Kirill Grushin; Alex Villalobos; Alexey Y Koyfman; Michael F Schmid; Svetla Stoilova-McPhie
Journal:  Sci Rep       Date:  2015-06-17       Impact factor: 4.379

Review 8.  A new recombinant factor VIII: from genetics to clinical use.

Authors:  Elena Santagostino
Journal:  Drug Des Devel Ther       Date:  2014-12-12       Impact factor: 4.162

Review 9.  Turoctocog alfa (NovoEight®)--from design to clinical proof of concept.

Authors:  Mirella Ezban; Knud Vad; Marianne Kjalke
Journal:  Eur J Haematol       Date:  2014-05-28       Impact factor: 2.997

10.  Molecular determinants of the factor VIII/von Willebrand factor complex revealed by BIVV001 cryo-electron microscopy.

Authors:  James R Fuller; Kevin E Knockenhauer; Nina C Leksa; Robert T Peters; Joseph D Batchelor
Journal:  Blood       Date:  2021-05-27       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.